International Myeloma Workshop Conference 2011

In this review:

Role of cereblon in antimyeloma activity of IMiDs
GSK-3 as a primary target of IMiDs and biomarker of clinical response
Bortezomib/dexamethasone/cyclophosphamide/lenalidomide in previously untreated MM
Lenalidomide/thalidomide/dexamethasone in relapsed/refractory MM
Carfilzomib/lenalidomide/dexamethasone in newly diagnosed MM
Bortezomib-based mobilisation in MM
Enoxaparin vs. aspirin as thromboprophylaxis in newly diagnosed MM
Consolidation bortezomib/thalidomide/dexamethasone: skeletal effects
Weekly bortezomib in relapsed/refractory MM
Bendamustine in MM patients with renal impairment
Smouldering MM: lenalidomide/dexamethasone vs. no treatment
SC vs. IV bortezomib in relapsed MM

Please login below to download this issue (PDF)

Subscribe